Distribution of rs1801279 and rs1799930 Polymorphisms in NAT2 Gene among Population in Kupang, Nusa Tenggara Timur, Indonesia

Edhyana Sahiratmadja, Simeon Penggoam, Ani Melani Maskoen, Alvinsyah Adhityo Pramono, Dias Aryani, Nurul Setia Rahayu, Ramdan Panigoro


BACKGROUND: N-acetyltransferase-2 (NAT2) enzyme, encoded by NAT2 gene, plays a key role in metabolism of anti-tuberculosis (TB) drug isoniazid. Polymorphisms in NAT2 gene may result in different responses to TB therapy. Since TB prevalence in the eastern part of Indonesia is high, the aim of this study is to explore the distribution of NAT2 gene polymorphisms among population from Kupang, Nusa Tenggara Timur.

METHODS: A total of 234 respondents were included from Kupang in 2012. Polymorphisms of NAT2 gene were examined using mass screening platform and the genotypes distribution were presented in percentage. To confirm NAT2 gene polymorphisms, polymerase chain reaction (PCR)-sequencing was performed in a subset of population.

RESULTS: The polymorphisms of NAT2 gene showed that the distribution of rs1801279 for GG genotype was 100%; whereas the genotype distribution of rs1799930 for GG, GA and AA was 57%, 35.1% and 7.9%, respectively. In a subset of individuals (n13), acetylator status was well determined by PCR-sequencing, resulting in individual with wild type fast acetylator (NAT2*4; n4), intermediate (NAT2*4/*5 or NAT2*4/*6 or NAT2*4/*7; n7) and poor acetylators (NAT2*6/*6 or NAT2*7/*7; n2).

CONCLUSION: The amino acid change in rs1799930 result in intermediate and poor acetylator status in Kupang population. This may lead to suboptimal response of TB therapy. Assessing acetylator status before TB therapy is important and may serve as personalized INH therapy.

KEYWORDS: NAT2 gene, polymorphism, acetylator status, Kupang

Full Text:



Sotsuka T, Sasaki Y, Hirai S, Yamagishi F, Ueno K. Association of isoniazid-metabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo. 2011; 25: 803-12, PMID.

Hein DW, Doll MA. Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics J. 2012; 13: 31-41, CrossRef.

Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F, et al. Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci. 2008; 33: 187-95, PMID.

Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tubercu-losis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013; 69: 1091-101, CrossRef.

Kang TS, Jin SK, Lee JE, Woo SW, Roh J. Comparison of genetic polymorphisms of the NAT2 gene between Korean and four other ethnic groups. J Clin Pharm Ther. 2009; 34: 709-18, CrossRef.

Chamorro JG, Castagnino JP, Musella RM, Frias A, Aranda FM, De Larrañaga GF. The distribution of allelic and genotypic frequencies of N-Acetyltransferase-2 variants in an Argentine population. J Infect Dev Ctries. 2012; 6: 671-4, CrossRef.

Ebeshi BU, Bolaji OO, Masimirembwa CM. Arylamine N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms frequencies in Nigerian populations. Afr J Pharm and Pharmacol Res. 2011; 1: 001-6, article.

Yuliwulandari R, Sachrowardi Q, Nishida N, Takasu M, Batubara L, Susmiarsih TP, et al. Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature. J Hum Genet. 2008; 53: 201-9, CrossRef.

World Health Organization (WHO). Global Tuberculosis Report. Geneva: WHO; 2015, article.

Lin CH, Yeakley JM, McDaniel TK, Shen R. Medium- to highthroughput SNP genotyping using VeraCode microbeads. Methods Mol Biol. 2009; 496: 129-42, CrossRef.

Ministry of Health Republic of Indonesia. Basic Health Research. Jakarta: Ministry of Health Republic of Indonesia; 2013, article.

Mayo Clinic: Mayo Medical Laboratories [Internet]. NAT2 N-Acetyltrasferase 2 Gene (NAT2), Full Gene Sequence [cited 2017 Mar 25]. Available from: http://www.mayomedicallaboratories.com/.

Rutherford ME, Ruslami R, Maharani W, Yulita I, Lovell S, Van Crevel R, et al. Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation. BMC Res Notes. 2012; 5: 7, CrossRef.

Sabbagh A, Langaney A, Darlu P, Gérard N, Krishnamoorthy R, Poloni ES. Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet. 2008; 9: 21, CrossRef.

Kukongviriyapan V, Prawan A, Tassaneyakul W, Aiemsa-Ard J, Warasiha B. Arylamine N-acetyltransferase-2 genotypes in the Thai population. Br J Clin Pharmacol. 2003; 55: 278-81, PMID.

SNPedia [Internet]. Rs1801279 [updated 2012 Dec 5; cited 2013 Sep 1]. Available from: http://snpedia.com/.

Campbell MC, Tishkoff SA. African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet. 2008; 9: 403-33, CrossRef.

Parwati I, van Crevel R, Sudiro M, Alisjahbana B, Pakasi T, Kremer K, van der Zanden A, van Soolingen D. Mycobacterium tuberculosis population structures differ significantly on two Indonesian Islands. J Clin Microbiol. 2008; 46: 3639-45, CrossRef.

SNPedia [Internet]. Rs1799930 [updated 2012 Dec 5; cited 2013 Sep 1]. Available from: http://snpedia.com/.

Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics J. 1994; 4: 125-34, PMID.

Kita T, Tanigawara Y, Chikazawa S, Hatanaka H, Sakaeda T, Komada F, et al. N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients. Biol Pharm Bull. 2001; 24: 544-9, PMID.

Lv X, Tang S, Xia Y, Zhang Y, Wu S, Yang Z, et al. NAT2 genetic polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Chinese community population. Ann Hepatol. 2012; 11: 700-7, PMID.

Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, et al. Should we use N-acetyltransferase type 2 genotyping to personalize isoniaziddoses? Antimicrob Agents Chemother. 2005; 49: 1733-8, CrossRef.

Yuliwulandari R, Susilowati RW, Wicaksono BD, Viyati K, Prayuni K, Razari I, et al. NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis. J Hum Genet. 2016; 61: 533-7, CrossRef.

DOI: https://doi.org/10.18585/inabj.v10i1.330

Indexed by:






The Prodia Education and Research Institute